The commission has already signed contracts with AstraZeneca, Sanofi- GlaxoSmithKline, Janssen, and BioNTech/Pfizer, and is in exploratory talks with Moderna. This portfolio will ensure Europe is well-prepared for vaccination once the vaccines have been proven safe and effective. Member states can also decide to donate the vaccine to lower or middle-income countries or to redirect it to other European countries. To date, the commission has secured at least 1.2 billion doses.

Germany-based CureVac signed an $89 million loan agreement with the European Investment Bank on July 6 for the development and large-scale production of vaccines, including its COVID-19 vaccine candidate. The company is developing a new class of vaccines based on messenger RNA delivered by lipid nanoparticles.

CureVac released positive interim phase I data for its CVnCoV vaccine candidate on November 10 and is planning to initiate a phase IIb/III clinical trial by the end of 2020.

Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine
Pfizer and BioNTech, developers of BNT162b2, a messenger RNA-based SARS-CoV-2 vaccine candidate, have reached an agreement with the European Commission...

J&J to supply EU with 200M COVID-19 vaccine doses
Johnson & Johnson has received approval from the European Commission to supply 200 million doses of Janssen Pharmaceutical's COVID-19 vaccine...

Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate,...

Sanofi, GSK get $2.1B for COVID-19 vaccine
The U.S. government will provide up to $2.1 billion to Sanofi and GlaxoSmithKline (GSK) for the development and manufacturing of a recombinant protein-based...

Europe raises 7.4B euros for coronavirus response
On May 4, a group of nations and the European Commission raised 7.4 billion euros ($8 billion U.S.) to help make up for funding shortfalls in...